Vascular Control Systems, Inc. develops medical devices. The company's services include, Doppler guided clamp for bilateral temporary occlusion of the uterine arteries and Doppler guided hemostat for blood loss control during open surgical procedures. Vascular Control Systems was founded in 1998 and is headquartered in San Juan Capistrano, CA.

The Baker Heart and Diabetes Institute, commonly known as the Baker Institute, is an Australian independent medical research institute headquartered in Melbourne, Victoria. Established in 1926, the institute is one of Australia's oldest medical research organisations with an historical focus on cardiovascular disease. In 2008, it became the country's first medical research institute to target diabetes, heart disease, obesity and their complications at the basic, clinical and population health levels.

Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. The Company has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, and inflammatory diseases, and has preclinical programs in other diseases and disorders. The company’s product portfolio includes EYLEA, an aflibercept injection; ARCALYST, a rilonacept Injection for subcutaneous use; ZALTRAP for metastatic colorectal cancer; trap fusion proteins; and fully human monoclonal antibodies. On March 26, 2012, it was announced that Sanofi and Regeneron are in development with a new cholesterol drug which will help reduce cholesterol up to 72%. Regeneron Pharmaceuticals was founded in 1988 and is currently headquartered in New York, USA.

Provides blood pressure monitoring products and software for patient information systems

Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH.

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing, and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease, and Alzheimer’s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionized the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck’s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centers in Denmark and China.

ONO Pharmaceutical is focused on the production, purchase, and sale of pharmaceuticals and diagnostic reagents on prescription pharmaceuticals. The company focuses on drug discovery leads that are high in certainty and globally competitive. The company was started in 1717 in Dosho-machi, Osaka. Throughout its 300-year history, ONO has dedicated itself to developing innovative and breakthrough pharmaceutical products.

Beijing Huaguan Pharmaceutical Technology Co., Ltd., established on 2016-03-01, Business scope includes technology development,technical consulting,Technical Services,technology transfer,Technology Promotion;Sales of chemical products(Free of Hazardous Chemicals);Technical testing;Technology Import and Export,Import and export,Agent import and export.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Santen Pharmaceutical Co., Ltd engages in the manufacture and sale of pharmaceutical products and medical devices. It operates through the following segments: Pharmaceuticals and Others. The Pharmaceuticals segment includes prescription ophthalmic drugs, anti-rheumatic pharmaceuticals, and over-the-counter products. The Others segment offers medical equipment and devices. The company was founded by Kenkichi Tagushi in 1890 and is headquartered in Osaka, Japan.

Runfang (Beijing) Biomedical Research Institute Co., Ltd., established on 2017-07-28, Business scope includes general items:Medical Research and Experimental Development;Agricultural Science Research and Experimental Development;Natural science research and experimental development;Engineering and Technology Research and Experimental Development;Health Consulting Services(Does not include medical services);Socioeconomic Advisory Services;software development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Organize cultural and artistic exchange activities;Conference and Exhibition Services;Computer System Services;Sales of Class I Medical Devices;Sales of Class II Medical Devices;electronics sales;Retailing of computer software, hardware and auxiliary equipment;Machinery sales;Chemical product sales(No licensed chemical products);Import and export;Technology Import and Export;Import and export agency.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:pharmaceutical production;Veterinary drug production;Class III medical device business;Production of Class III Medical Devices;Veterinary drug business;Drug Wholesale;Drug retail.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Jiangsu Zhengrui Pharmaceutical Technology Co., Ltd., established on 2018-11-13, Business scope includes pharmaceuticals(Contains chemicals,biological drug,traditional Chinese medicine)research and development,Sales;Pharmaceutical commissioned production(For details, see Drug Registration Approval Document for Drug Marketing Authorization Holders);Medical Technology Consulting and Technology Promotion Services.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Compo Haohan (Beijing) Technology Co., Ltd., established on 2019-04-01, Business scope includes technology development,Technology Promotion,technology transfer,technical consulting,Technical Services;software development;Information system integration service;Information Consulting;Computer System Services;design,make,acting,Place an ad;computer system integration;Sales of medical devicesΙ,Class II,electronic product,communication equipment,computer,Software and Auxiliary Equipment,household appliances,Daily Chemicals,cleaning tools,daily necessities;Import and export,Technology Import and Export,Agent import and export;Health Advisory(Except for medical treatment activities subject to approval);Conference and Exhibition Services;internet sales(Except for products that require a license for sale);family service(Business activities that do not meet the general requirements of domestic service shall not be carried out);Cleaning Services;Organize cultural and artistic exchange activities(without show);internet data service(Data Centers in Internet Data Services,PUEvalue in1.4Except for the above cloud computing data centers);Information processing and storage support services(Data centers in information processing and storage support services,PUEvalue in1.4Except for the above cloud computing data centers);Sales of Class III medical devices;sell food;Internet information service;Health food management.(Market entities independently choose business projects in accordance with the law,Carry out business activities;sell food;Internet information service;Sales of Class III medical devices;Health food business and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Jiangsu Bofa Biotechnology Co., Ltd., established on 2015-09-14, Business scope includes biotechnology,Blood separation and purification technology,Medical Device Technology,Research and development of consumable software technology,Serve,transfer;Class III6845Blood purification equipment and blood purification appliances,6870software manufacturing,processing,Sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

LuMend, Inc. used to develop medical devices. It delivered technology and services to interventional cardiologists, radiologists and vascular surgeons specializing in endovascular techniques for the treatment of peripheral vascular diseases. The company also provided a clinical solution to chronic total occlusions. LuMend was founded by John B. Simpson & Matthew R. Selmon in 1996 and was headquartered in Redwood City, CA.

Agility Partners develops invasive device therapy for the treatment of congestive heart failure which is inserted into the patient's aorta thus providing significant improvement in blood flow. They provide CHF and H-SAR devices. Their H-SAR device implantable pump inserts through a small hole in the artery using a sheath.

Jilin Tuohua Biotechnology Co., Ltd., established on 2010-12-31, Business scope includes research and development of biomedical technology,consult,transfer,Serve;Cell Technology Services,Tissue storage service,Exhibition display service,Reagent sales(Does not contain dangerous goods);Acquisition of agricultural and sideline products;Cosmetic production;cosmetic;Health Products Sales;consultation service,Cleaning Products;Daily necessities sales;Medical device production;Sales;lease;Investment and management of medical institutions;Research and development of biological gene detection technology;consult;Serve;disinfection products(Does not contain dangerous goods)Production;Sales;(The following items are limited to branch operations)Hemodialysis Technology;beauty service;chemical reagent(Does not contain dangerous goods)Production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments).

Proassist is a nursing & medical embedded and control system development company.

deCODE genetics, Inc. (Icelandic: Íslensk erfðagreining) is a biopharmaceutical company based in Reykjavík, Iceland. The company was founded in 1996 by Kári Stefánsson to identify human genes associated with common diseases using population studies, and apply the knowledge gained to guide the development of candidate drugs. The company isolated genes believed to be involved in cardiovascular disease, cancer and schizophrenia, among other diseases (the company's research concerning the latter is said to represent the first time a gene has been identified by two independent studies to be associated with schizophrenia).